Skip to main content

Marina to Sell off Non-RNAi Asset to Cypress Bioscience

Premium

Marina Biotech said this week that it has signed an agreement to sell its patents and technology related to carbetocin, a long-acting analog of the hormone oxytocin, to Cypress Bioscience for an initial fee of $750,000 and potential milestones of up to $27 million.

According to Marina, the drug may potentially be used as an autism treatment. Nastech Pharmaceutical, the predecessor company of Marina, had advanced the compound through two phase I dose-escalation studies.

"While we remain focused on building value around our RNAi drug discovery platforms, the sale of our carbetocin assets to Cypress is another example of our efforts to monetize the legacy assets of our predecessor company," Marina President and CEO Michael French said in a statement. "We hope to use the potential downstream financial opportunity to further fund our RNAi-based drug discovery and development efforts."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.